机器学习用于新生儿万古霉素个体化给药
本研究基于大型新生儿万古霉素数据集,利用多种机器学习算法构建预测稳态谷浓度(C0)和稳态AUC0-24的模型,并进行外部验证。结果显示,Catboost-based C0-ML模型预测准确性较群体药动学模型提高42.5%,虚拟试验中80.3%新生儿达到C0 10-20 mg/L的目标,远高于国际标准剂量组的37.7-61.5%。
要点
- C0-ML模型可在治疗前预测C0,外部验证准确性较群体药动学模型提高42.5%。
- 虚拟试验中ML优化剂量使80.3%新生儿C0达10-20 mg/L,高于标准剂量的37.7-61.5%。
- 获得首个TDM结果后,AUC-ML模型可预测AUC0-24,外部验证准确性达80.3%。
核心结论
- 基于C0和AUC0-24的机器学习模型可分别用于新生儿万古霉素治疗前个体化剂量推荐和首次TDM后的剂量调整。
研究设计与样本
- 从大型新生儿万古霉素数据集中获取C0,通过贝叶斯后验估计获得个体AUC0-24,使用多种机器学习算法建模,并用外部数据集评估预测性能。
主要发现
- C0-ML模型结合给药方案和9个协变量可在治疗前预测C0,外部验证预测准确性较群体药动学模型提高42.5%。
- 虚拟试验中,ML优化剂量使80.3%的虚拟新生儿达到C0 10-20 mg/L的目标,而国际标准剂量组为37.7-61.5%。
- 获得TDM测量的C0后,AUC-ML模型结合C0和9个协变量可预测AUC0-24,外部验证预测准确性达80.3%。
关键数值与推荐
- C0目标范围为10-20 mg/L。
- C0-ML模型外部验证预测准确性较群体药动学模型提高42.5%。
- AUC-ML模型外部验证预测准确性为80.3%。
临床怎么用
- 治疗前可使用C0-ML模型结合给药方案和9个协变量预测C0,辅助制定个体化初始剂量。
- 获得首个TDM C0结果后,可使用AUC-ML模型预测AUC0-24,用于剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: High variability in vancomycin exposure in neonates requires advanced individualized dosing regimens. Achieving steady-state trough concentration (C0) and steady-state area-under-curve (AUC0-24) targets is important to optimize treatment. The objective was to evaluate whether machine learning (ML) can be used to predict these treatment targets to calculate optimal individual dosing regimens under intermittent administration conditions. METHODS: C0 were retrieved from a large neonatal vancomycin dataset. Individual estimates of AUC0-24 were obtained from Bayesian post hoc estimation. Various ML algorithms were used for model building to C0 and AUC0-24. An external dataset was used for predictive performance evaluation. RESULTS: Before starting treatment, C0 can be predicted a priori using the Catboost-based C0-ML model combined with dosing regimen and nine covariates. External validation results showed a 42.5% improvement in prediction accuracy by using the ML model compared with the population pharmacokinetic model. The virtual trial showed that using the ML optimized dose; 80.3% of the virtual neonates achieved the pharmacodynamic target (C0 in the range of 10-20 mg/L), much higher than the international standard dose (37.7-61.5%). Once therapeutic drug monitoring (TDM) measurements (C0) in patients have been obtained, AUC0-24 can be further predicted using the Catboost-based AUC-ML model combined with C0 and nine covariates. External validation results showed that the AUC-ML model can achieve an prediction accuracy of 80.3%. CONCLUSION: C0-based and AUC0-24-based ML models were developed accurately and precisely. These can be used for individual dose recommendations of vancomycin in neonates before treatment and dose revision after the first TDM result is obtained, respectively.
引用
- Tang BH, Zhang JY, Allegaert K, et al. Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates. Clin Pharmacokinet. 2023. PMID: 37300630. doi:10.1007/s40262-023-01265-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。